Comparison of a generic to disease targeted health-related quality-of-life measures for multiple sclerosis

被引:123
作者
Vickrey, BG
Hays, RD
Genovese, BJ
Myers, LW
Ellison, GW
机构
[1] UNIV CALIF LOS ANGELES, DEPT MED, LOS ANGELES, CA 90095 USA
[2] RAND CORP, HLTH SCI PROGRAM, SANTA MONICA, CA 90407 USA
关键词
health related quality of life; generic measures; disease targeted measures; multiple sclerosis; SF-36; relative validity;
D O I
10.1016/S0895-4356(97)00001-2
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Evaluation of the relative contributions of generic and disease-targeted measures to assessing health-related quality of life (HRQOL) for chronic conditions is needed to help in selection of appropriate measures. We administered a generic HRQOL measure (the Short Form-36 [SF-36]), three disease-targeted supplemental scales to the SF-36, and two disease-targeted HRQOL instruments to 171 adults with multiple sclerosis. Most scales yielded adequate variability, internal consistency reliability, and test-retest reliability. The relationships between each measure and four primary ''criterion'' variables were assessed: overall symptom severity in the prior year; ambulation status; days unable to work or attend school in the prior month; and a rating of overall quality of life. Results indicate that the disease-targeted scales provided unique information not captured by the generic measure. We conclude that if a generic measure of HRQOL is desirable for a given study of multiple sclerosis, additional information will be gained by supplementing that measure with selected scales. (C) 1997 Elsevier Science Inc.
引用
收藏
页码:557 / 569
页数:13
相关论文
共 48 条
[1]  
Andrew F., 1976, SOCIAL INDICATORS WE
[2]  
BOMBARDIER C, 1995, MED CARE, V33, pAS131
[3]  
BROWNSCOMBE I, 1990, Neurology, V40, P142
[4]  
BROWNSCOMBE IA, 1990, THESIS U W ONTARIO O
[5]  
Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297
[6]   REPRODUCIBILITY AND RESPONSIVENESS OF HEALTH-STATUS MEASURES - STATISTICS AND STRATEGIES FOR EVALUATION [J].
DEYO, RA ;
DIEHR, P ;
PATRICK, DL .
CONTROLLED CLINICAL TRIALS, 1991, 12 (04) :S142-S158
[7]   INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
DUQUETTE, P ;
GIRARD, M ;
DESPAULT, L ;
DUBOIS, R ;
KNOBLER, RL ;
LUBLIN, FD ;
KELLEY, L ;
FRANCIS, GS ;
LAPIERRE, Y ;
ANTEL, J ;
FREEDMAN, M ;
HUM, S ;
GREENSTEIN, JI ;
MISHRA, B ;
MULDOON, J ;
WHITAKER, JN ;
EVANS, BK ;
LAYTON, B ;
SIBLEY, WA ;
LAGUNA, J ;
KRIKAWA, J ;
PATY, DW ;
OGER, JJ ;
KASTRUKOFF, LF ;
MOORE, GRW ;
HASHIMOTO, SA ;
MORRISON, W ;
NELSON, J ;
GOODIN, DS ;
MASSA, SM ;
GUTTERIDGE, E ;
ARNASON, BGW ;
NORONHA, A ;
REDER, AT ;
MARTIA, R ;
EBERS, GC ;
RICE, GPA ;
LESAUX, J ;
JOHNSON, KP ;
PANITCH, HS ;
BEVER, CT ;
CONWAY, K ;
WALLENBERG, JC ;
BEDELL, L ;
VANDENNOORT, S ;
WEINSHENKER, B ;
WEISS, W ;
REINGOLD, S ;
PACHNER, A ;
TAYLOR, W .
NEUROLOGY, 1993, 43 (04) :655-661
[8]   A CRITICAL-APPRAISAL OF THE QUALITY OF QUALITY-OF-LIFE MEASUREMENTS [J].
GILL, TM ;
FEINSTEIN, AR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (08) :619-626
[9]   LOW-DOSE (7.5-MG) ORAL METHOTREXATE REDUCES THE RATE OF PROGRESSION IN CHRONIC PROGRESSIVE MULTIPLE-SCLEROSIS [J].
GOODKIN, DE ;
RUDICK, RA ;
MEDENDORP, SV ;
DAUGHTRY, MM ;
SCHWETZ, KM ;
FISCHER, J ;
VANDYKE, C .
ANNALS OF NEUROLOGY, 1995, 37 (01) :30-40
[10]  
Gulick E E, 1991, West J Nurs Res, V13, P195, DOI 10.1177/019394599101300204